Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are specific, antibiotic-resistant bacteria that spread by contact and can cause serious infections. MRSA can be spread by touching articles that have been contaminated by the skin of an infected or colonized person, such as towels, sheets, and wound dressings; VRE can be transmitted by touching articles soiled by an infected person鈥檚 feces. Both of these bacteria survive well on hands and for weeks on inanimate objects. Colonization occurs when bacteria are present on or in the body (i.e., nose, skin, rectum, moist areas of the body and the newborn鈥檚 umbilicus) without causing illness.
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of such infections. They may either kill or inhibit the growth of bacteria.
The global VRE and MRSA Antibiotic market size was valued at US$ 4354 million in 2023 and is forecast to a readjusted size of USD 5677 million by 2030 with a CAGR of 3.9% during review period.
The market for is VRE and MRSA antibiotic market fragmented with players such as Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical. Among the companies, pfizer contributed 17% of the market, which is the biggest in 2020.In terms of product, linezolid is the largest segment, with a share over 38%. And in terms of application, the largest application is hospitals.
This report is a detailed and comprehensive analysis for global VRE and MRSA Antibiotic market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global VRE and MRSA Antibiotic market size and forecasts, in consumption value ($ Million), sales quantity (M Units), and average selling prices (USD/Unit), 2019-2030
Global VRE and MRSA Antibiotic market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Units), and average selling prices (USD/Unit), 2019-2030
Global VRE and MRSA Antibiotic market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Units), and average selling prices (USD/Unit), 2019-2030
Global VRE and MRSA Antibiotic market shares of main players, shipments in revenue ($ Million), sales quantity (M Units), and ASP (USD/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for VRE and MRSA Antibiotic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global VRE and MRSA Antibiotic market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Lilly, Sanofi Aventis, Merck, Fresenius Kabi, Xellia Pharmaceuticals (Novo Holdings), Zhejiang Medicine, Zhejiang Hisun Pharmaceutical, North China Pharmaceutical, Korea United Pharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
VRE and MRSA Antibiotic market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Vancomycin
Teicoplanin
Linezolid
Daptomycin
Others
麻豆原创 segment by Application
Hospitals
Clinics
Others
Major players covered
Pfizer
Lilly
Sanofi Aventis
Merck
Fresenius Kabi
Xellia Pharmaceuticals (Novo Holdings)
Zhejiang Medicine
Zhejiang Hisun Pharmaceutical
North China Pharmaceutical
Korea United Pharm
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe VRE and MRSA Antibiotic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of VRE and MRSA Antibiotic, with price, sales quantity, revenue, and global market share of VRE and MRSA Antibiotic from 2019 to 2024.
Chapter 3, the VRE and MRSA Antibiotic competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the VRE and MRSA Antibiotic breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and VRE and MRSA Antibiotic market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of VRE and MRSA Antibiotic.
Chapter 14 and 15, to describe VRE and MRSA Antibiotic sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global VRE and MRSA Antibiotic Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Vancomycin
1.3.3 Teicoplanin
1.3.4 Linezolid
1.3.5 Daptomycin
1.3.6 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global VRE and MRSA Antibiotic Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Others
1.5 Global VRE and MRSA Antibiotic 麻豆原创 Size & Forecast
1.5.1 Global VRE and MRSA Antibiotic Consumption Value (2019 & 2023 & 2030)
1.5.2 Global VRE and MRSA Antibiotic Sales Quantity (2019-2030)
1.5.3 Global VRE and MRSA Antibiotic Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer VRE and MRSA Antibiotic Product and Services
2.1.4 Pfizer VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Pfizer Recent Developments/Updates
2.2 Lilly
2.2.1 Lilly Details
2.2.2 Lilly Major Business
2.2.3 Lilly VRE and MRSA Antibiotic Product and Services
2.2.4 Lilly VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Lilly Recent Developments/Updates
2.3 Sanofi Aventis
2.3.1 Sanofi Aventis Details
2.3.2 Sanofi Aventis Major Business
2.3.3 Sanofi Aventis VRE and MRSA Antibiotic Product and Services
2.3.4 Sanofi Aventis VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Sanofi Aventis Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck VRE and MRSA Antibiotic Product and Services
2.4.4 Merck VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Merck Recent Developments/Updates
2.5 Fresenius Kabi
2.5.1 Fresenius Kabi Details
2.5.2 Fresenius Kabi Major Business
2.5.3 Fresenius Kabi VRE and MRSA Antibiotic Product and Services
2.5.4 Fresenius Kabi VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Fresenius Kabi Recent Developments/Updates
2.6 Xellia Pharmaceuticals (Novo Holdings)
2.6.1 Xellia Pharmaceuticals (Novo Holdings) Details
2.6.2 Xellia Pharmaceuticals (Novo Holdings) Major Business
2.6.3 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Product and Services
2.6.4 Xellia Pharmaceuticals (Novo Holdings) VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Xellia Pharmaceuticals (Novo Holdings) Recent Developments/Updates
2.7 Zhejiang Medicine
2.7.1 Zhejiang Medicine Details
2.7.2 Zhejiang Medicine Major Business
2.7.3 Zhejiang Medicine VRE and MRSA Antibiotic Product and Services
2.7.4 Zhejiang Medicine VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Zhejiang Medicine Recent Developments/Updates
2.8 Zhejiang Hisun Pharmaceutical
2.8.1 Zhejiang Hisun Pharmaceutical Details
2.8.2 Zhejiang Hisun Pharmaceutical Major Business
2.8.3 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Product and Services
2.8.4 Zhejiang Hisun Pharmaceutical VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
2.9 North China Pharmaceutical
2.9.1 North China Pharmaceutical Details
2.9.2 North China Pharmaceutical Major Business
2.9.3 North China Pharmaceutical VRE and MRSA Antibiotic Product and Services
2.9.4 North China Pharmaceutical VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 North China Pharmaceutical Recent Developments/Updates
2.10 Korea United Pharm
2.10.1 Korea United Pharm Details
2.10.2 Korea United Pharm Major Business
2.10.3 Korea United Pharm VRE and MRSA Antibiotic Product and Services
2.10.4 Korea United Pharm VRE and MRSA Antibiotic Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Korea United Pharm Recent Developments/Updates
3 Competitive Environment: VRE and MRSA Antibiotic by Manufacturer
3.1 Global VRE and MRSA Antibiotic Sales Quantity by Manufacturer (2019-2024)
3.2 Global VRE and MRSA Antibiotic Revenue by Manufacturer (2019-2024)
3.3 Global VRE and MRSA Antibiotic Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of VRE and MRSA Antibiotic by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 VRE and MRSA Antibiotic Manufacturer 麻豆原创 Share in 2023
3.4.3 Top 6 VRE and MRSA Antibiotic Manufacturer 麻豆原创 Share in 2023
3.5 VRE and MRSA Antibiotic 麻豆原创: Overall Company Footprint Analysis
3.5.1 VRE and MRSA Antibiotic 麻豆原创: Region Footprint
3.5.2 VRE and MRSA Antibiotic 麻豆原创: Company Product Type Footprint
3.5.3 VRE and MRSA Antibiotic 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global VRE and MRSA Antibiotic 麻豆原创 Size by Region
4.1.1 Global VRE and MRSA Antibiotic Sales Quantity by Region (2019-2030)
4.1.2 Global VRE and MRSA Antibiotic Consumption Value by Region (2019-2030)
4.1.3 Global VRE and MRSA Antibiotic Average Price by Region (2019-2030)
4.2 North America VRE and MRSA Antibiotic Consumption Value (2019-2030)
4.3 Europe VRE and MRSA Antibiotic Consumption Value (2019-2030)
4.4 Asia-Pacific VRE and MRSA Antibiotic Consumption Value (2019-2030)
4.5 South America VRE and MRSA Antibiotic Consumption Value (2019-2030)
4.6 Middle East & Africa VRE and MRSA Antibiotic Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
5.2 Global VRE and MRSA Antibiotic Consumption Value by Type (2019-2030)
5.3 Global VRE and MRSA Antibiotic Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
6.2 Global VRE and MRSA Antibiotic Consumption Value by Application (2019-2030)
6.3 Global VRE and MRSA Antibiotic Average Price by Application (2019-2030)
7 North America
7.1 North America VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
7.2 North America VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
7.3 North America VRE and MRSA Antibiotic 麻豆原创 Size by Country
7.3.1 North America VRE and MRSA Antibiotic Sales Quantity by Country (2019-2030)
7.3.2 North America VRE and MRSA Antibiotic Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
8.2 Europe VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
8.3 Europe VRE and MRSA Antibiotic 麻豆原创 Size by Country
8.3.1 Europe VRE and MRSA Antibiotic Sales Quantity by Country (2019-2030)
8.3.2 Europe VRE and MRSA Antibiotic Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific VRE and MRSA Antibiotic 麻豆原创 Size by Region
9.3.1 Asia-Pacific VRE and MRSA Antibiotic Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific VRE and MRSA Antibiotic Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 South Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
10.2 South America VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
10.3 South America VRE and MRSA Antibiotic 麻豆原创 Size by Country
10.3.1 South America VRE and MRSA Antibiotic Sales Quantity by Country (2019-2030)
10.3.2 South America VRE and MRSA Antibiotic Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa VRE and MRSA Antibiotic Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa VRE and MRSA Antibiotic Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa VRE and MRSA Antibiotic 麻豆原创 Size by Country
11.3.1 Middle East & Africa VRE and MRSA Antibiotic Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa VRE and MRSA Antibiotic Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 VRE and MRSA Antibiotic 麻豆原创 Drivers
12.2 VRE and MRSA Antibiotic 麻豆原创 Restraints
12.3 VRE and MRSA Antibiotic Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of VRE and MRSA Antibiotic and Key Manufacturers
13.2 Manufacturing Costs Percentage of VRE and MRSA Antibiotic
13.3 VRE and MRSA Antibiotic Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 VRE and MRSA Antibiotic Typical Distributors
14.3 VRE and MRSA Antibiotic Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
听
听
*If Applicable.
